InvestorsHub Logo
Followers 43
Posts 866
Boards Moderated 0
Alias Born 03/08/2014

Re: Al4door post# 186567

Sunday, 08/19/2018 10:44:46 PM

Sunday, August 19, 2018 10:44:46 PM

Post# of 732085
Al4door:

I don't think that LP threw longs under the bus as you call it. The decimation of the share price was caused by lack of reported results. This was all FUDDED by investors going the other way and perhaps illegally. Right now, we have no smoking gun proof. LP and company decided that silence was the best policy. I don't think saying anything short of great results would have saved the pps. The length of the trial and the uncertainty it has bred has been a major cause of the decimation. Obviously, vultures took advantage of all this and drove the pps lower. But LP has put her money where her belief is. Sure she has monetised Cognate and maybe, to some extent, it was on longs' backs, but LP is not stupid and is not going to waste good money after bad if she does not believe that the odds are in favour of success. She has a lot more info and experts versus the general investor and has skin in the game. These small biotechs are risky. Attacks are common with investors going the other way. And there are good arguments for it. I am betting in favour of success. IMHO, I think that argument is better. LP's willingness to put money in regardless of how she may have raised it has got to be a positive. Yes, she has a better deal than most retail, but she stepped up to the plate, so I don't really blame her for getting a better deal. If she succeeds, so do longs. We may not get the $100, $50 or even $20 we had hoped for but at my base investment, and I averaged down considerably, I would be happy with $3 which is reasonable if DC VAX L is even somewhat successful. I don't like where the pps are and I am as frustrated as the next investor. The pub is certainly very encouraging and so is the support from a number of physicians/scientists. I think that the pps are severely undervalued. Shorts and bashers don't. Differences of opinions are what make a horse race. I believe that DC VAX L will receive approval and it will be broad as it appears to work across all groups to a greater or lesser extent. Each tumour(s) is different and personalised. That is what DC VAX L is all about. JMHO.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News